Brentuximab vedotin

Generic Name
Brentuximab vedotin
Brand Names
Adcetris
Drug Type
Biotech
Chemical Formula
-
CAS Number
914088-09-8
Unique Ingredient Identifier
7XL5ISS668
Background

Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug labe...

Indication

Brentuximab vedotin is indicated in adult patients for the treatment of previously untreated stage III or IV classical Hodgkin's lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine. It is also indicated for the treatment of cHL post-autologous hematopoietic stem cell transplantation (auto-HSCT) in patients at high risk of relapse or ...

Associated Conditions
CD30-expressing Mycosis Fungoides (MF), Classical Hodgkin's Lymphoma, Peripheral T-Cell Lymphoma (PTCL), Primary Cutaneous Anaplastic Large Cell Lymphoma, Systemic Anaplastic Large Cell Lymphoma, Stage 3 Classical Hodgkin's Lymphoma
Associated Therapies
-
Clinical Trials
Related News

Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors

Phase 2
Completed
Conditions
Germ Cell Cancer
Interventions
Drug: Brentuximab Vedotin
First Posted Date
2013-05-10
Last Posted Date
2018-02-07
Lead Sponsor
Fondazione Michelangelo
Target Recruit Count
9
Registration Number
NCT01851200
Locations
🇮🇹

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Mi, Italy

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

Not Applicable
Terminated
Conditions
Peripheral T-Cell Lymphoma
Interventions
Drug: Brentuximab vedotin
First Posted Date
2013-04-26
Last Posted Date
2017-01-19
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Target Recruit Count
1
Registration Number
NCT01841021
Locations
🇺🇸

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Brentuximab Vedotin + Re-induction Chemotherapy for AML

First Posted Date
2013-04-12
Last Posted Date
2020-04-14
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
22
Registration Number
NCT01830777
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia

First Posted Date
2013-03-08
Last Posted Date
2019-01-29
Lead Sponsor
Jason Robert Gotlib
Target Recruit Count
10
Registration Number
NCT01807598
Locations
🇺🇸

Stanford University, School of Medicine, Stanford, California, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas

First Posted Date
2013-03-05
Last Posted Date
2021-09-01
Lead Sponsor
Northwestern University
Target Recruit Count
20
Registration Number
NCT01805037
Locations
🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

Tufts University School of Medicine, Boston, Massachusetts, United States

🇺🇸

Northwestern University, Chicago, Illinois, United States

Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma

First Posted Date
2013-01-31
Last Posted Date
2021-10-28
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
46
Registration Number
NCT01780662
Locations
🇺🇸

University of Mississippi Medical Center, Jackson, Mississippi, United States

🇺🇸

Saint Joseph's Regional Medical Center, Paterson, New Jersey, United States

🇺🇸

Valley Children's Hospital, Madera, California, United States

and more 113 locations

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

First Posted Date
2013-01-28
Last Posted Date
2021-11-30
Lead Sponsor
Seagen Inc.
Target Recruit Count
452
Registration Number
NCT01777152
Locations
🇺🇸

Weill Cornell Medical College, New York, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center - Basking Ridge, Basking Ridge, New Jersey, United States

🇮🇱

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

and more 141 locations

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

First Posted Date
2013-01-18
Last Posted Date
2024-08-09
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
41
Registration Number
NCT01771107
Locations
🇺🇸

Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

🇺🇸

Virginia Mason Medical Center, Seattle, Washington, United States

🇺🇸

Fred Hutchinson Cancer Center, Seattle, Washington, United States

and more 25 locations

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

First Posted Date
2012-10-30
Last Posted Date
2024-06-11
Lead Sponsor
Seagen Inc.
Target Recruit Count
131
Registration Number
NCT01716806
Locations
🇺🇸

Wenatchee Valley Medical Center, Wenatchee, Washington, United States

🇺🇸

James Cancer Hospital / Ohio State University, Columbus, Ohio, United States

🇺🇸

Swedish Cancer Institute, Seattle, Washington, United States

and more 51 locations

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

First Posted Date
2012-10-23
Last Posted Date
2024-02-20
Lead Sponsor
Takeda
Target Recruit Count
1334
Registration Number
NCT01712490
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy